PortfoliosLab logo
NXTC vs. AUPH
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NXTC and AUPH is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

NXTC vs. AUPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

NXTC:

-0.91

AUPH:

1.06

Sortino Ratio

NXTC:

-1.50

AUPH:

1.91

Omega Ratio

NXTC:

0.83

AUPH:

1.21

Calmar Ratio

NXTC:

-0.68

AUPH:

0.57

Martin Ratio

NXTC:

-1.46

AUPH:

3.18

Ulcer Index

NXTC:

46.26%

AUPH:

15.18%

Daily Std Dev

NXTC:

76.00%

AUPH:

43.56%

Max Drawdown

NXTC:

-99.71%

AUPH:

-87.58%

Current Drawdown

NXTC:

-99.47%

AUPH:

-76.30%

Fundamentals

Market Cap

NXTC:

$13.92M

AUPH:

$1.06B

EPS

NXTC:

-$1.77

AUPH:

$0.27

PS Ratio

NXTC:

9.52

AUPH:

4.28

PB Ratio

NXTC:

0.25

AUPH:

3.02

Total Revenue (TTM)

NXTC:

$0.00

AUPH:

$247.30M

Gross Profit (TTM)

NXTC:

-$701.00K

AUPH:

$218.23M

EBITDA (TTM)

NXTC:

-$50.34M

AUPH:

$54.34M

Returns By Period

In the year-to-date period, NXTC achieves a -36.19% return, which is significantly lower than AUPH's -12.69% return.


NXTC

YTD

-36.19%

1M

2.50%

6M

-57.95%

1Y

-68.05%

3Y*

-49.85%

5Y*

-56.40%

10Y*

N/A

AUPH

YTD

-12.69%

1M

-4.39%

6M

-11.51%

1Y

44.65%

3Y*

-11.42%

5Y*

-13.15%

10Y*

8.43%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


NextCure, Inc.

Aurinia Pharmaceuticals Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

NXTC vs. AUPH — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NXTC
The Risk-Adjusted Performance Rank of NXTC is 77
Overall Rank
The Sharpe Ratio Rank of NXTC is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of NXTC is 55
Sortino Ratio Rank
The Omega Ratio Rank of NXTC is 88
Omega Ratio Rank
The Calmar Ratio Rank of NXTC is 99
Calmar Ratio Rank
The Martin Ratio Rank of NXTC is 77
Martin Ratio Rank

AUPH
The Risk-Adjusted Performance Rank of AUPH is 7979
Overall Rank
The Sharpe Ratio Rank of AUPH is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of AUPH is 8484
Sortino Ratio Rank
The Omega Ratio Rank of AUPH is 7777
Omega Ratio Rank
The Calmar Ratio Rank of AUPH is 7474
Calmar Ratio Rank
The Martin Ratio Rank of AUPH is 7979
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NXTC vs. AUPH - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current NXTC Sharpe Ratio is -0.91, which is lower than the AUPH Sharpe Ratio of 1.06. The chart below compares the historical Sharpe Ratios of NXTC and AUPH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

NXTC vs. AUPH - Dividend Comparison

Neither NXTC nor AUPH has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NXTC vs. AUPH - Drawdown Comparison

The maximum NXTC drawdown since its inception was -99.71%, which is greater than AUPH's maximum drawdown of -87.58%. Use the drawdown chart below to compare losses from any high point for NXTC and AUPH.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

NXTC vs. AUPH - Volatility Comparison

NextCure, Inc. (NXTC) has a higher volatility of 30.17% compared to Aurinia Pharmaceuticals Inc. (AUPH) at 7.96%. This indicates that NXTC's price experiences larger fluctuations and is considered to be riskier than AUPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

NXTC vs. AUPH - Financials Comparison

This section allows you to compare key financial metrics between NextCure, Inc. and Aurinia Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00M50.00M60.00M70.00M202120222023202420250
62.47M
(NXTC) Total Revenue
(AUPH) Total Revenue
Values in USD except per share items